The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
A definitive model for predicting absolute risk of coronary heart disease (CHD) in male and female people with Type II diabetes is not yet available. This paper provides an equation for estimating the risk of new CHD events in people with Type II diabetes, based on data from 4540 U.K. Prospective Diabetes Study male and female patients. Unlike previously published risk equations, the model is diabetes-specific and incorporates glycaemia, systolic blood pressure and lipid levels as risk factors, in addition to age, sex, ethnic group, smoking status and time since diagnosis of diabetes. All variables included in the final model were statistically significant (P<0.001, except smoking for which P=0.0013) in likelihood ratio testing. This model provides the estimates of CHD risk required by current guidelines for the primary prevention of CHD in Type II diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The lower the CAD risk, the higher the chance of a false positive”
From Exercise and Type 2 Diabetes (2010) · cites this paper as [248]
In the citing paper
“During the entire follow-up period, the rate of death among patients in the conventionaltherapy group was 50%, a finding that underscores the poor prognosis for such patients in the absence of intensive treatment.20”
From Effect of a multifactorial intervention on mortality in type 2 diabetes (2008) · cites this paper as [20]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationStratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Self-citationPrevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Cited by
Items 501–600 of 1,000
Rossom, R. C., Crain, A. L., O’Connor, P. J., Waring, S. C., Hooker, S. A., Ohnsorg, K. A., Taran, A. M., Kopski, K. M., & Sperl‐Hillen, J. M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.0202 · Cited by 29
Nguyen, M. T., Cosson, E., Valensi, P. E., Poignard, P., Nitenberg, A., & Pham, I. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.12.006 · Cited by 25
A Novel Model for Metabolic Syndrome Risk Quantification Based on Areal Similarity Degree
Jeong, S., Jo, Y. M., Shim, S., Choi, Y.-J., & Youn, C. (2013) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2013.2286197 · Cited by 25
“This fact is highlighted in other algorithms used to predict CVD risk using regression coefficients to assign different weights to risk factors [16], [17], and it is apparent from studies that examined the risk of CVD in persons with one or two components of MS versus three or more [18].”
Methodfor the Italian Diabetes and Exercise Study 2 (IDES_2) Investigators, Balducci, S., Sacchetti, M., Haxhi, J., Orlando, G., Zanuso, S., Cardelli, P., Cavallo, S., D’Errico, V., Ribaudo, M. C., et al. (2015) · Trials · doi:10.1186/s13063-015-1088-0 · Cited by 25
Dimitriu‐Leen, A. C., Scholte, A. J. H. A., van Rosendael, A. R., van den Hoogen, I. J., Kharagjitsingh, A. V., Wolterbeek, R., Knuuti, J. M., Kroft, L. J. M., Delgado, V., Jukema, J. W., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.12.023 · Cited by 26
Viswanathan, V., Jamthikar, A. D., Gupta, D., Puvvula, A., Khanna, N. N., Saba, L., Višković, K., Mavrogeni, S. I., Laird, J. R., Pareek, G., et al. (2020) · Angiology · doi:10.1177/0003319720941730 · Cited by 25
“Conventional cardiovascular risk calculators provide risk prediction using patient demographics, blood biomarkers, and clinical parameters.(5-17) Such CV risk factors do not fully explain plaque growth and its morphological variations.”
BackgroundYang, Y., Kim, H., Kim, S., Moon, M. K., & Korean Society of Lipid and Atherosclerosis (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0448 · Cited by 26
“In the UK Prospective Diabetes Study (UKPDS), lowdensity lipoprotein cholesterol (LDL-C) was the strongest predictor of coronary heart disease in patients with type 2 diabetes mellitus (T2DM) among several risk factors for CVD, and each 39 mg/dL increase in LDL-C increased the coronary heart disease risk by about 60%…”
BackgroundAsimakopoulou, K. G., Fox, C., Spimpolo, J., Marsh, S., & Skinner, T. C. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02473.x · Cited by 25
Panayidou, K., Gsteiger, S., Egger, M., Kilcher, G., Carreras, M., Efthimiou, O., Debray, T. P. A., Trelle, S., Hummel, N., & on behalf of the GetReal methods review group (2016) · Research Synthesis Methods · doi:10.1002/jrsm.1202 · Cited by 24
van Dieren, S., Kengne, A. P., Chalmers, J. P., Beulens, J. W. J., Cooper, M. E., Grobbee, D. E., Harrap, S. B., Mancia, G., Neal, B. C., Patel, A. A., et al. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.05.002 · Cited by 26
“[15] Stevens RJ, Kothari V, Adler AI, Stratton IM.”
BackgroundMethodGeiger, M. J., Mehta, C. R., Turner, J. R., Arbet‐Engels, C., Hantel, S., Hirshberg, B., Koglin, J., Mendzelevski, B., Sager, P. T., Shapiro, D., et al. (2014) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479014549860 · Cited by 24
Development of a life expectancy table for individuals with type 1 diabetes
Tran‐Duy, A., Knight, J., Clarke, P., Svensson, A., Eliasson, B., & Palmer, A. J. (2021) · Diabetologia · doi:10.1007/s00125-021-05503-6 · Cited by 24
“Currently, risk information predominantly relates to the risk of CVD over a 5 or 10 year period [12, 13], and includes both risk charts [14] and risk calculators [15].”
Background(NDR), O. B. O. T. N. D. R., Guðbjörnsdóttir, S., Eliasson, B., Eeg‐Olofsson, K., Zethelius, B., & Cederholm, J. (2011) · Diabetologia · doi:10.1007/s00125-011-2218-1 · Cited by 27
Risk predictive modelling for diabetes and cardiovascular disease
Kengne, A. P., Masconi, K. L., Mbanya, V. N., Lekoubou, A., Echouffo-Tcheugui, J. B., & Matsha, T. E. (2013) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.853025 · Cited by 27
Gobardhan, S. N., Dimitriu‐Leen, A. C., van Rosendael, A. R., van Zwet, E. W., Roos, C. J., Oemrawsingh, P. V., Kharagjitsingh, A. V., Jukema, J. W., Delgado, V., Schalij, M. J., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.11.029 · Cited by 24
Cheng, T., Lai, H., Yu, S., Chiu, W.-C., Hsu, C., Chen, J., & Chen, Y. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2018-000723 · Cited by 24
Optimization of Sequential Decision Making for Chronic Diseases: From Data to Decisions
Denton, B. T. (2018) · doi:10.1287/educ.2018.0184 · Cited by 29
Hirai, H., Asahi, K., Yamaguchi, S., Mori, H., Satoh, H., Iseki, K., Moriyama, T., Yamagata, K., Tsuruya, K., Fujimoto, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39049-w · Cited by 27
Shao, H., Shi, L., & Fonseca, V. A. (2020) · Diabetes Care · doi:10.2337/dc20-0227 · Cited by 24
Biological Surrogates for Enhancing Cardiovascular Risk Prediction in Type 2 Diabetes Mellitus
Clair, L. S., & Ballantyne, C. M. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.008 · Cited by 24
Hohberg, C., Pfützner, A., Forst, T. M., Lübben, G., Karagiannis, E., Borchert, M., & Schöndorf, T. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00975.x · Cited by 24
Review article: hyperlipidaemia and cardiovascular risk
Bertolotti, M., Maurantonio, M., Gabbi, C., Anzivino, C., & Carulli, N. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02591.x · Cited by 30
Long term cardiovascular risk models’ combination
Paredes, S., Rocha, T., Carvalho, P., Henriques, J. M. O., Harris, M., & Morais, J. (2011) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2010.12.015 · Cited by 27
Bagust, A., Evans, M., Beale, S., Home, P., Perry, A., & Stewart, M. W. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624001-00002 · Cited by 24
Currenti, W., Losavio, F., Quiete, S., Alanazi, A. M., Messina, G., Polito, R., Ciolli, F., Zappalà, R. S., Galvano, F., & Cincione, R. I. (2023) · Nutrients · doi:10.3390/nu16010095 · Cited by 23
Mohamed, H. F., Allam, M. M., Hamdy, N. A., Ghazy, R. M., & Emara, R. H. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211056307 · Cited by 23
STOUGAARD, E. B., Rossing, P. R., Vistisen, D., Banks, P. L., Girard, M., Davies, M. J., & Persson, F. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15047 · Cited by 23
“The United Kingdom Prospective Diabetes Study (UKPDS) risk engine is well known for use in type 2 diabetes.(24) However, this risk score will not apply to type 1 diabetes because of obvious differences between the two types of diabetes, with longer diabetes duration in type 1 diabetes and more obesity in type 2 diabet…”
BackgroundWhat matters in ADVANCE and ADVANCE‐ON
Hamet, P. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01509.x · Cited by 27
“developed by the Framingham Study Group, which have considered diabetes as a ‘yes/no’ variable, being just one of many prognostic variables, and those of the UKPDS [36,37], which took into consideration glucose levels and duration of diagnosed diabetes.”
BackgroundInfluentialMerry, A. H. H., Boer, J. M. A., Schouten, L. J., Ambergen, T., Steyerberg, E. W., Feskens, E. J. M., Verschuren, W. M. M., Gorgels, A. P. M., & van den Brandt, P. A. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826711410256 · Cited by 28
Yong, T. Y., Phillipov, G., & Phillips, P. J. J. (2007) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb01078.x · Cited by 23
Sun, X., He, J., Ji, X., Zhao, Y., Lou, H.-Y., Song, X., Shan, L., Kang, Y.-X., Zeng, W.-H., Pang, X.-H., et al. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.196564 · Cited by 28
Atherosclerotic Cardiovascular Risk in Japan
Nojiri, S., & Daida, H. (2017) · Japanese Clinical Medicine · doi:10.1177/1179066017712713 · Cited by 24
Cardiovascular risk estimated by UKPDS risk engine algorithm in diabetes
Kavarić, N., Klisic, A. N., & Ninić, A. (2018) · Open Medicine · doi:10.1515/med-2018-0086 · Cited by 23
Decision models in type 2 diabetes mellitus: A systematic review
Li, J., Bao, Y., Chen, X., & Tian, L. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01742-6 · Cited by 25
Kiadaliri, A., Clarke, P., Gerdtham, U., Nilsson, P. M., Eliasson, B., Guðbjörnsdóttir, S., & Carlsson, K. S. (2013) · Journal of Diabetes Research · doi:10.1155/2013/241347 · Cited by 23
“These risk factors are commonly used in clinical risk equations [14, 15] as well as health economic simulation models [16].”
BackgroundMultiple risk factor intervention reduces carotid atherosclerosis in patients with type 2 diabetes
Tripolt, N. J., Narath, S. H., Eder, M., Pieber, T. R., Wascher, T. C., & Sourij, H. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-95 · Cited by 22
“These can be calculated for any given duration of type 2 diabetes based on current age, sex, ethnicity, smoking status, presence or absence of atrial fibrillation and levels of HbA1c, systolic blood pressure, total cholesterol and HDL cholesterol [15].”
BackgroundRautio, N., Jokelainen, J. J., Pölönen, A., Oksa, H. H., Peltonen, M., Vanhala, M. J., Puolijoki, H., Moilanen, L., Tuomilehto, J., Uusitupa, M. I. J., et al. (2014) · European Journal of Cardiovascular Nursing · doi:10.1177/1474515114521713 · Cited by 25
On the importance of global cardiovascular risk assessment in people with type 2 diabetes
Echouffo-Tcheugui, J. B., & Kengne, A. P. (2013) · Primary care diabetes · doi:10.1016/j.pcd.2013.03.002 · Cited by 25
“This was based on the assumption that a unit increment in the duration of diagnosed diabetes contributes more to risk estimates than a unit increment in age [54].”
BackgroundMethodSchaan, B. D., Neto, J. A. D. F., Moreira, L. B., Ledur, P. D. S., Mattos, L. A., Magnoni, D., Précoma, D. B., Machado, C. A., Brasileiro, A. L. D. S., Pena, F. M., et al. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.021 · Cited by 23
de Graaf, G., Postmus, D., Westerink, J., & Buskens, E. (2018) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-018-0105-z · Cited by 24
Chowdhury, M., & Turin, T. C. (2020) · Journal of Primary Health Care · doi:10.1071/hc19087 · Cited by 28
Wong, C. K. H., Wu, T., Wong, S. K., Law, B. T. T., Grieve, E., Ng, E. K., Wu, O., & Lam, C. L. K. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa075 · Cited by 23
Pfohl, M., Schädlich, P. K., Dippel, F. W., & Koltermann, K. C. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.713879 · Cited by 24
Cleveringa, F. G. W., Meulenberg, M. G. G., Gorter, K. J., van den Donk, M., & Rutten, G. E. H. M. (2008) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2007.12.003 · Cited by 22
Berk, K. A., Buijks, H., Özcan, B., Spijker, A. V., Busschbach, J. J. V., & Sijbrands, E. J. G. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-1026 · Cited by 23
“Cardiovascular riskprofile by use of the UKPDS risk engine [49]:”
MethodShould All Diabetic Patients Be Treated With a Statin?
Kamari, Y., Bitzur, R., Cohen, H., Shaish, A., & Harats, D. (2009) · Diabetes Care · doi:10.2337/dc09-s344 · Cited by 23
“, UKPDS risk engine, Cardiovascular Life Expectancy Model) can be used to estimate vascular risk (24).”
BackgroundLim, T., Yun, J., Cha, S., Song, K., Yoo, K., Ahn, Y., Park, Y., & Ko, S. (2016) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.030 · Cited by 23
Alrawahi, A. H., Lee, P. J., Anqoudi, Z. A., Busaidi, A. A., Al-Rabaani, M., Almahrouqi, F., & Busaidi, A. M. A. (2017) · Oman Medical Journal · doi:10.5001/omj.2017.20 · Cited by 22
Lipid-lowering therapy in people with type 2 diabetes
Colagiuri, S., & Best, J. D. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200212000-00004 · Cited by 23
Mata‐Cases, M., Prado-Lacueva, C. D., Salido-Valencia, V., Fernández-Bertolín, E., Casermeiro, J., García-Durán, M., Jabalera, S., & Martin, M. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02503.x · Cited by 24
Katakami, N., Takahara, M., Kaneto, H., Sakamoto, K., Yoshiuchi, K., Irie, Y., Kubo, F., Katsura, T., Yamasaki, Y., Kosugi, K., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0331 · Cited by 22
“The UK Prospective Diabetes Study Risk Engine (URE), which estimates CHD risk using conventional risk factors such as age, sex, smoking, systolic blood pressure, total cholesterol, HDL-cholesterol, plus the diabetes-specific factors duration of diabetes and HbA1c, was also used as a model for predicting risk of CVE (2…”
MethodThe Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation
Ye, W., Brändle, M., Brown, M. B., & Herman, W. H. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0304 · Cited by 23
“Although the transition between no CHD and MI was governed by the risk engine developed by the United Kingdom Prospective Diabetes Study (UKPDS) Research Group, 19 the other transition probabilities were not re-lated to the levels of cardiovascular risk factors.”
Kim, B. H., Jang, J., Kwon, Y. S., Kim, J. H., Kim, I. J., & Lee, C. W. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.1.88 · Cited by 26
Bjerg, L., Nicolaisen, S. K., Christensen, D. H., Nielsen, J. S., Andersen, S. T., Jørgensen, M. E., Jensen, T. S., Sandbæk, A., Andersen, H., Beck‐Nielsen, H., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0010 · Cited by 23
Marcotte‐Chénard, A., Tremblay, D., Mony, M. M., Brochu, M., Dionne, I. J., Langlois, M., Mampuya, W. M., Morais, J. A., Tessier, D., & Riesco, É. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102233 · Cited by 24
Elevated Serum Free Light Chains Predict Cardiovascular Events in Type 2 Diabetes
Bellary, S., Faint, J. M., Assi, L. K., Hutchison, C. A., Harding, S. J., Raymond, N. T., & Barnett, A. H. (2014) · Diabetes Care · doi:10.2337/dc13-2227 · Cited by 21
Risk Scores for Prediction of Coronary Heart Disease: An Update
Wilson, P. W. F. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.001 · Cited by 21
Protopsaltis, I. D., Konstantinopoulos, P. A., Kamaratos, A. V., & Melidonis, A. I. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.277 · Cited by 21
Almeda‐Valdés, P., Ramos, D. C., Mehta, R., Gomez-Perez, F. J., & Aguilar-Salinas, C. A. (2010) · Current Diabetes Reviews · doi:10.2174/157339910790442646 · Cited by 23
Cleveringa, F. G. W., Gorter, K. J., van den Donk, M., Pijman, P., & Rutten, G. E. H. M. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0210 · Cited by 22
Lyon, A. W. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1040138 · Cited by 21
Life and Death in Denmark: Lessons About Diabetes and Coronary Heart Disease
Goldfine, A. B., & Beckman, J. A. (2008) · Circulation · doi:10.1161/circulationaha.108.767681 · Cited by 25
Erythrocyte membrane fluidity: A novel biomarker of residual cardiovascular risk in type 2 diabetes
Bianchetti, G., CEFALO, C. M. A., Ferreri, C., Sansone, A., Vitale, M., Serantoni, C., Abeltino, A., Mezza, T., Ferraro, P. M., Spirito, M. D., et al. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14121 · Cited by 21
“Furthermore, well-known CVD prediction scores, such as UK Prospective Diabetes Study (UKPDS) score 6 or the Systemic Coronary Risk Evaluation (SCORE), 7 have consistently failed in identifying subjects at greater risk of developing CVD within diabetic populations.”
MethodRiddell, M. A., Renwick, C., Wolfe, R. S., Colgan, S., Dunbar, J., Hagger, V. L., Absetz, P., & Oldenburg, B. F. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-843 · Cited by 22
“The primary outcome measure is cardiovascular disease (CVD) risk using the UKPDS risk calculation [16].”
MethodInfluentialPowers, B. J., King, J., Ali, R., Alkon, A., Bowlby, L. A., Edelman, D. E., Gentry, P., Grubber, J. M., Koropchak, C. M., Maciejewski, M. L., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.06.026 · Cited by 21
Ford, E. S., Li, C., & Sniderman, A. D. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-26 · Cited by 22
Colberg, S. R., Sigal, R. J., Fernhall, B., Regensteiner, J. G., Blissmer, B. J., Rubin, R. R., Chasan‐Taber, L., Albright, A. L., & Braun, B. (2010) · Cited by 21
Shivakumar, V., Kandhare, A. D., Rajmane, A. R., Adil, M., Ghosh, P., Lb, B., Saraf, M. N., & Bodhankar, S. L. (2014) · PubMed Central · Cited by 24
Ezenwaka, C. E., Dimgba, A., Okali, F., Teppany, S., Martina, R., Extavour, R. M., Verdine, D., Alida, S., Mayers, H., & Altheia, J. (2011) · PubMed · Cited by 22
Risk & Prevention Collaborative Group, Marzona, I., Avanzini, F., Lucisano, G., Tettamanti, M., Baviera, M., Nicolucci, A., & Roncaglioni, M. C. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0899-0 · Cited by 23
Hua, X., Lung, T. W.-C., Palmer, A. J., Si, L., Herman, W. H., & Clarke, P. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0466-0 · Cited by 23
“The UKPDS risk engine participated in the fourth Mount Hood Diabetes Challenge but was not included in this study as it does not quantify lifetime outcomes in terms of QALYs or LE [13].”
MethodArterial Stiffness in Type 1 Diabetes: The Case for the Arterial Wall Itself as a Target Organ
González-Clemente, J. M., Cano, A., Albert, L., Giménez‐Palop, O., Romero, A., Berlanga, E., Vendrell, J. J., & Llauradó, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163616 · Cited by 23
“As patients with diabetes are at very high CV risk, specific scores for predicting CV events are also available for both type 1 (T1D) [4] and type 2 (T2D) diabetes [5].”
BackgroundReducing vascular events risk in patients with dyslipidaemia: an update for clinicians
Hermans, M. P., & Fruchart, J. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622311413952 · Cited by 20
Rydén, L., estable, G. D. T. D. L. S. E. D. C. S. D. Y. T. D. L. C. I., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H. P., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.10.015 · Cited by 37
Physical Activity in Obese Type 2 Diabetes After Gastric Bypass or Medical Management
Panosian, J., Ding, S.-A., Wewalka, M., Simonson, D. C., GOEBEL-FABBRI, A. E., Foster, K., Halperin, F., Vernon, A. H., & Goldfine, A. B. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.07.019 · Cited by 24
An audit of structured diabetes care in a rural general practice
Ackermann, E. W., & Mitchell, G. K. (2006) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00473.x · Cited by 20
Mendis, S., O'Brien, E. T., Seedat, Y. K., & Yusuf, S. (2013) · International Journal of Hypertension · doi:10.1155/2013/878460 · Cited by 23
Kim, D., Baek, H.-I., Ha, K.-C., Cha, Y., & Park, S.-J. (2022) · Nutrients · doi:10.3390/nu14153159 · Cited by 20
Yang, H., Li, F., Chen, Z., Zhou, M., Xie, L.-F., Jin, Y., Li, Z., & Chen, G. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac642 · Cited by 21
Zafrir, B., Azaiza, M., Gaspar, T., Dobrecky‐Mery, I., Azencot, M., Lewis, B. S., Rubinshtein, R., & Halon, D. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.020 · Cited by 21
Herath, H. M. M., Weerarathna, T. P., & Umesha, D. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s90126 · Cited by 22
Bansal, D., Nayakallu, R., Gudala, K., Vyamasuni, R., & Bhansali, A. K. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.4.321 · Cited by 20
Luconi, M., Raimondi, L., Franco, A. D., & Mannucci, E. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.09.001 · Cited by 20
Electronic health record analysis via deep Poisson factor models
Henao, R., Lu, J. T., Lucas, J. E., Ferranti, J. M., & Carin, L. (2016) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · doi:10.5555/2946645.3053468 · Cited by 23
Cichosz, S. L., Jensen, M. H., & Hejlesen, O. K. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.11.005 · Cited by 21
Okada, K., Hoshide, S., Kato, M., Kanegae, H., Ishibashi, S., & Kario, K. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.14131 · Cited by 22
D’Onofrio, L., Mignogna, C., Carlone, A., Bellizzi, E., Guida, M., Moretti, C., Zampetti, S., Leto, G., Maddaloni, E., & Buzzetti, R. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108681 · Cited by 19
Feng, L., Lam, A. Y. R., Carmody, D., Lim, C. W., Tan, G. C. S., Goh, S., Bee, Y. M., & Jafar, T. H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259157 · Cited by 19
“To evaluate benefits of optimizing diabetes care, proportion of patients without microalbuminuria (UACR<30 mg/g) and 10-year risk of coronary heart disease (CHD) and stroke were calculated using the UK Prospective Diabetes Study (UKPDS) risk engine [19, 20].”
MethodSong, M., Alexander, C. M., Mavros, P., López, V. A. Q., Malik, S., Phatak, H. M., & Wong, N. D. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.10.011 · Cited by 21
Complicações macrovasculares do diabetes melito: peculiaridades clínicas, de diagnóstico e manejo
Triches, C. B., Schaan, B. D., Gross, J. L., & de Azevedo, M. J. (2009) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302009000600002 · Cited by 46
Wan, Q., Harris, M., Davies, G. P., Jayasinghe, U. W., Flack, J. R., Georgiou, A., Burns, J. R., & Penn, D. L. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01604.x · Cited by 19
Cost‐effectiveness of a risk‐based secondary screening programme of type 2 diabetes
Nagy, B., Zsólyom, A., Nagyjánosi, L., Merész, G., Steiner, T., Papp, E., Dessewffy, Z., Jermendy, G., Winkler, G., Kaló, Z., et al. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2791 · Cited by 20
Coronary risk in South Asians: role of ethnicity and blood sugar
Aarabi, M., & Jackson, P. R. (2004) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000140714.79273.c9 · Cited by 20
Lucioni, C., Mazzi, S., & Neeser, K. (2004) · PharmacoEconomics Italian Research Articles · doi:10.1007/bf03320626 · Cited by 19
Wei, J.-H., Chou, R., Huang, P., Lee, W., Chen, S.-C., & Lin, S. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.08.026 · Cited by 19
Ma, S., Zhang, M., Sun, W., Gao, Y., Jing, M., Gao, L., & Wu, Z. (2025) · Healthcare and Rehabilitation · doi:10.1016/j.hcr.2024.100006 · Cited by 23
Cosson, E., Nguyen, T. M., Hamo-Tchatchouang, E., Banu, I., Chiheb, S., Charnaux, N., & Valensi, P. E. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03215.x · Cited by 21
Weitzman, S., Greenfield, S., Billimek, J., Tabenkin, H., Shvartzman, P., Yehiel, E., Tandeter, H. B., Eilat‐Tsanani, S., & Kaplan, S. H. (2009) · PubMed · Cited by 18
Kaneko, M., Fujihara, K., Yamada, M. H., OSAWA, T., Yamamoto, M., Kitazawa, M., Matsubayashi, Y., Yamada, T., Seida, H., Kodama, S., et al. (2021) · Journal of Foot and Ankle Research · doi:10.1186/s13047-021-00474-8 · Cited by 18
“Age is an established independent risk factor for atherosclerosis and macrovascular complications in people with diabetes [14, 15].”
BackgroundJin, Q., Lau, E. S. H., Luk, A. O. Y., Ozaki, R., Chow, E., Cheng, F., So, T., Yeung, T., Loo, K.-M., Lim, C. K. P., et al. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108015 · Cited by 20
Metadata
- Authors
- STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M.
- Affiliations
- University of Oxford (GB)
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2001-12-01
- Volume
- 101
- Issue
- 6
- Pages
- 671
- ISSN
- 0143-5221 (ISSN-L)
- OpenAlex
- W2117191092
- Cited by
- 1,084
- References
- 51
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 10 · 2023: 33 · 2022: 44 · 2021: 60 · 2020: 46 · 2019: 42 · 2018: 47 · 2017: 42 · 2016: 39 · 2015: 60 · 2014: 66 · 2013: 68 · 2012: 59
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- coronary artery disease, type 2 diabetes, cardiovascular risk prediction, risk prediction model, glycemia, systolic blood pressure, serum lipids, primary prevention, smoking, sex differences
- MeSH terms
- Adult, Blood Pressure, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Lipids, Male, Middle Aged, Risk Factors, Smoking, Models, Statistical, Survival Rate, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.